Skip to main content
NIH funding notice RFA-AI-22-028

Partnerships for the Development of Novel Therapeutics to Combat Select Antibiotic Resistant Bacteria and Fungi (R01 Clinical Trial Not Allowed)

Closed on July 29, 2022.

Posted
April 5, 2022
Close date
July 29, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

6 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,834,631 in first-year total cost, median $991,875.

Most frequent study sections

  1. Special Emphasis Panel[ZAI1 PG-M (M1)]6

Most frequent institutions

  1. EMORY UNIVERSITY1
  2. J. CRAIG VENTER INSTITUTE, INC.1
  3. UNIVERSITY OF CALIFORNIA, SAN DIEGO1
  4. UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN1
  5. UNIVERSITY OF PITTSBURGH AT PITTSBURGH1
Competing awards under RFA-AI-22-028 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia1R01AI176554-01MEIER, ANGELANIZET, VICTORZHANG, LIANGFANGUNIVERSITY OF CALIFORNIA, SAN DIEGO, CA$1,027,000ZAI1
2023Monoclonal Antibody to Combat Pseudomonas Aeruginosa1R01AI176545-01GOLDBERG, JOANNA BEMORY UNIVERSITY, GA$1,021,806ZAI1
2023Host Directed Orynotide for MDR Gram Negative Bacterial Infections1R01AI176543-01SCHAAL, JUSTIN BLAINEUNIVERSITY OF SOUTHERN CALIFORNIA, CA$1,005,952ZAI1
2023FabI Inhibitors as Potent, Gut Microbiome-Sparing Antibiotics1R01AI176523-01HERGENROTHER, PAULUNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN, IL$977,797ZAI1
2023Optimization, Manufacturing and Testing of a Lead Therapeutic Bacteriophage Cocktail for the Treatment of Antibiotic-Resistant Klebsiella pneumoniae Infections1R01AI176546-01FOUTS, DERRICK EJ. CRAIG VENTER INSTITUTE, INC., CA$921,333ZAI1
2023Developing a novel class of peptide antibiotics targeting carbapenem-resistant Gram-negative organisms1R01AI176537-01DI, YUANPU PETERLI, JIANUNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA$880,743ZAI1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-AI-22-028: Partnerships for the Development of Novel Therapeutics to Combat Select Antibiotic Resistant Bacteria and Fungi (R01 Clinical Trial Not Allowed) | ScienceDex | ConductScience